Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lesinurad Monotherapy in Gout (LIGHT)
NCT01508702Phase 3Completed
- Sponsor
- Ardea Biosciences, Inc.
- Start
- Jan 2012
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in gout comparing Lesinurad 400 mg with Placebo (2 arms). Primary endpoint: Proportion of Subjects With an sUA Level That is < 6.0 mg/dL at 6 months. Started Jan 2012; status: completed.
02
Drugs
lesinurad
03
Conditions
gout
Beyond the preview
Go deeper on NCT01508702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01508702.